318eP Therapeutic outcomes of PD-1 vs PD-L1 inhibitors in metastatic colorectal cancer: A meta-analysis of survival and safety
Immune checkpoint inhibitors (ICIs) targeting PD-1 and PD-L1 have revolutionized the treatment of multiple solid tumors, but their relative efficacy in metastatic colorectal cancer (mCRC) remains unclear. Therefore, this study aims to compare the survival outcomes and safety of PD-1 versus PD-L1 inhibitors in mCRC using data from randomized controlled trials (RCTs).
Authors
- Y. Al-Sadoon
- R. Al-Dulaimi
- Y. Alassi
- M. Al-Kubaisi
- M.M. Saber
- A. Shorbagi
- A. Abusaqer
- O. Hamodat
- A. Mohamad
- S. Almuzainy
Institutions
- University of Sharjah (AE)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2025.101517
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00